However, the widespread implementation of SGLT2 inhibitors in patients with HFrEF and also in patients with HFpEF regardless of T2DM suggest that new biomarkers such irisin are considered useful in the context of improving the discriminative power of current models, even if NT-proBNP levels remain respectively lower. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.